Tanino H - Search Results

1

Identification of Breast Cancer Stem Cells Using a Newly Developed Long-acting Fluorescence Probe, C5S-A, Targeting ALDH1A1.

Okamoto A, Funakoshi Y, Oe M, Takai R, Suto H, Nagatani Y, Nishimura M, Imamura Y, Kunihisa T, Kiyota N, Miki K, Ohe K, Tanino H, Minami H. Okamoto A, et al. Among authors: tanino h. Anticancer Res. 2022 Mar;42(3):1199-1205. doi: 10.21873/anticanres.15586. Anticancer Res. 2022. PMID: 35220209

2

A newly developed hexamethylmelamine derivative, SAE9 with both antitumor and aromatase-inhibitory activity.

Tanino H, Kubota T, Yamada Y, Koh JI, Takeuchi T, Kase S, Furukawa T, Takahashi M, Fukuda S, Ogose N, et al. Tanino H, et al. Anticancer Res. 1993 May-Jun;13(3):623-6. Anticancer Res. 1993. PMID: 8317890

3

Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data.

Kuo TH, Kubota T, Watanabe M, Furukawa T, Kase S, Tanino H, Saikawa Y, Ishibiki K, Kitajima M, Hoffman RM. Kuo TH, et al. Among authors: tanino h. Anticancer Res. 1993 May-Jun;13(3):627-30. Anticancer Res. 1993. PMID: 8391244

4

Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.

Kase S, Kubota T, Watanabe M, Furukawa T, Tanino H, Ishibiki K, Teramoto T, Kitajima M. Kase S, et al. Among authors: tanino h. Anticancer Res. 1993 Mar-Apr;13(2):369-73. Anticancer Res. 1993. PMID: 8517649

5

Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues.

Kubota T, Furukawa T, Tanino H, Oura S, Murata H, Yuasa S, Morita K, Ueno J, Kozakai R, Yano T. Kubota T, et al. Among authors: tanino h. Anticancer Res. 1998 Mar-Apr;18(2A):967-72. Anticancer Res. 1998. PMID: 9615748

6

Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.

Nishimiya H, Kosaka Y, Yamashita K, Minatani N, Kikuchi M, Ema A, Nakamura K, Waraya M, Sengoku N, Tanino H, Kuranami M, Watanabe M. Nishimiya H, et al. Among authors: tanino h. Anticancer Res. 2014 Jan;34(1):259-68. Anticancer Res. 2014. PMID: 24403472

7

[A Case of Primary Lymphoma of the Breast with Hepatic Cirrhosis].

Saito A, Okamoto A, Konishi M, Shimada N, Fukunaga M, Sugitani Y, Tanino H, Fukushima T, Oka K. Saito A, et al. Among authors: tanino h. Gan To Kagaku Ryoho. 2019 Feb;46(2):380-382. Gan To Kagaku Ryoho. 2019. PMID: 30914567 Japanese.

8

Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.

Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino H, Yamada K, Narui K, Kimura K, Akazawa K, Kohno N; JONIE STUDY GROUP. Hayashi M, et al. Among authors: tanino h. Anticancer Res. 2019 Aug;39(8):4305-4314. doi: 10.21873/anticanres.13596. Anticancer Res. 2019. PMID: 31366522 Clinical Trial.

9

Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.

Yamamoto J, Murata T, Sugisawa N, Higuchi T, Tashiro Y, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Shimoya K, Nomura T, Kurebayashi J, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM. Yamamoto J, et al. Among authors: tanino h. Anticancer Res. 2020 May;40(5):2475-2479. doi: 10.21873/anticanres.14217. Anticancer Res. 2020. PMID: 32366391

10

A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.

Yamamoto J, Murata T, Tashiro Y, Higuchi T, Sugisawa N, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Hongo A, Nomura T, Saitoh W, Moriya T, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM. Yamamoto J, et al. Among authors: tanino h. Anticancer Res. 2020 May;40(5):2509-2514. doi: 10.21873/anticanres.14221. Anticancer Res. 2020. PMID: 32366395

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

154 results

Search Page